Sunday, September 14, 2014

Top 10 Clean Energy Companies To Own For 2014

Stocks finished the week on the plus side, as the Dow hit a new high, and the broader market held its own against more bearish investors who are arguing more forcefully that the long bull market has to come to an end at some point. Several stocks helped to build some excitement for market participants, and Clean Energy Fuels (NASDAQ: CLNE  ) , Universal Display (NASDAQ: OLED  ) , and Nuverra Environmental Solutions (NYSE: NES  ) were among the best-performing stocks in the market Friday.

Source: Clean Energy Fuels.

Clean Energy Fuels jumped 12% as the natural-gas fueling station network operator reported much better conditions in its business than investors had expected. A 24% jump in gallons delivered helped reverse sluggishness in earlier quarters, and even though gains in dollar-value revenue were limited, adjusted sales soared 43% once you take out one-time items from the previous year. The expiration of crucial tax credits had a big impact on Clean Energy Fuels' income statement, reversing a year-ago profit, and raising questions about whether the company can get back to break-even levels quickly. For now, though, investors seem satisfied with Clean Energy Fuels' strategy to emphasize rising volume and station expansion.

Top 10 Net Payout Yield Companies To Invest In Right Now: BGC Partners Inc.(BGCP)

BGC Partners, Inc. operates as a financial intermediary to the financial markets specializing in the brokering of various financial products. It provides electronic marketplaces, including government bond markets, spot foreign exchange, foreign exchange options, corporate bonds, and credit default swaps in various financial markets through its eSpeed- and BGC Trader- branded trading platform which can be accessed through its high speed data network, over the Internet, or third party communication networks. The company?s brokerage services include trade execution, broker-dealer services, clearing, processing, information, and other back office services, as well as cover various products, including fixed income securities, interest rate swaps, foreign exchange, equities, equity derivatives, credit derivatives, commodities, futures, and structured products. It also provides financial technology solutions, market data, and analytics related to financial instruments and markets . In addition, the company offers customized screen-based market solutions, which enables its clients to develop a marketplace, trade with their customers, issue debt, trade odd lots, access program trading interfaces, and access its network and intellectual property. Further, it licenses intellectual property portfolio and software solutions to various financial markets participants; and provides software development, software maintenance, customer support, infrastructure, and internal technology services to support electronic trading platforms. The company serves banks, broker-dealers, investment banks, trading firms, hedge funds, governments, investment firms, professional trading firms, futures commission merchants, and other professional market participants and financial institutions in the United States, the United Kingdom, France, Asia, Europe, Africa, the Middle East, and other Americas. The company was founded in 1999 and is based in New York, New York.

Advisors' Opinion:
  • [By Brian Womack]

    ��t�� a defensive strategy because R&D costs are going up and the number of customers is going down,��said Amir Anvarzadeh, a manager of Japanese equity sales at BGC Partners Inc. (BGCP) in Singapore. ��his tells you there�� a problem in the industry.��

  • [By Eric Volkman]

    BGC Partners (NASDAQ: BGCP  ) is waxing optimistic about its current quarter. The company updated its previously issued guidance, indicating that its nearly complete Q2 will come in at the higher end of the range for revenues and EPS. The former was for distributable earnings revenue of $435 million-$465 million, while the latter anticipated pre-tax distributable earnings of $42 million-$53 million.

Top 10 Clean Energy Companies To Own For 2014: CTS Corporation (CTS)

CTS Corporation engages in the design, manufacture, assembly, and sale of electronic components and sensors, as well as the provision of electronics manufacturing services. It offers automotive sensors and actuators used in commercial or consumer vehicles; electronic components used in communications infrastructure and computer markets; components used in computer and other high-speed applications, switches, resistor networks, and potentiometers; and fabricated piezoelectric materials and substrates used primarily in medical, industrial, defense and aerospace, and computer markets. The company markets and sells its products through its sales engineers, independent manufacturers� representatives, and distributors. It has operations in China, Japan, Scotland, Singapore, India, Taiwan, and the United States. CTS Corporation was founded in 1896 and is based in Elkhart, Indiana.

Advisors' Opinion:
  • [By Seth Jayson]

    CTS (NYSE: CTS  ) reported earnings on July 22. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended June 30 (Q2), CTS missed estimates on revenues and beat expectations on earnings per share.

  • [By Marc Bastow]

    When earnings reports roll in, so do the dividend increases. This week, we saw a veritable tidal wave of dividend increases, from Megacap stocks like Halliburton (HAL) and Whole Foods (WFM) to smaller players like� CTS Corporation (CTS), companies were scrambling to boost their dividend payouts. A total of 23 companies increased their dividends this week.

Top 10 Clean Energy Companies To Own For 2014: Imprimis Pharmaceuticals Inc (IMMY)

Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company�� Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company�� lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.

Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it exerts its localized anti-inflammatory and analgesic effect. Transdel is the Company�� transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.

Advisors' Opinion:
  • [By John Udovich]

    So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

Top 10 Clean Energy Companies To Own For 2014: Odyssey Marine Exploration Inc.(OMEX)

Odyssey Marine Exploration, Inc. provides shipwreck exploration services for use in insurance investigations, and search and recovery operations to governments and deep-ocean mineral exploration companies. The company?s shipwreck projects consist of various activities, including research and development, and search operations; archaeological excavation and recovery operations; and conservation, recording, and documentation. It also sells shipwreck findings, including coins and other mass-produced cargo, cultural collections, and replicas to collectors, museums, and other institutions. Odyssey Marine Exploration, Inc. was founded in 1986 and is headquartered in Tampa, Florida.

Advisors' Opinion:
  • [By Jonathan Yates]

    Investors around the world are becoming more aware of the potential riches to be made by companies in the sea treasure recovery industry such as J.D. Hutt (PINK JABA) and Odyssey Marine Exploration (NASDAQ: OMEX) due to the media attention being paid to the raising of the Concordia. More than $60 billion rests on the ocean floor in gold (NYSE: GLD), silver (NYSE: SLV), and other valuables. As detailed in a previous article on this site, Odyssey Marine Exploration just presented at the 2013 Gateway Conference.

  • [By Sean Williams]

    Odyssey Marine Exploration (NASDAQ: OMEX  )
    I love a good metals play as much as any Fool around here, but Odyssey Marine is certainly not on the buy list. Odyssey Marine is a salvage company that searches for, recovers, and monetizes metals and minerals found on the ocean floor. Make no mistake about it, the job is as cool as it sounds; unfortunately, "cool" doesn't always translate into solid profits.

Top 10 Clean Energy Companies To Own For 2014: International Tower Hill Mines Ltd (THM)

International Tower Hill Mines Ltd. (ITH) is an exploration-stage company. The Company is engaged in the business of acquiring, exploring and evaluating mineral properties, and either joint venturing or developing these properties further or disposing of them when the evaluation is completed. As of December 31, 2011, the Company controlled a 100% interest in its Livengood project in Alaska, the United States. The Livengood property is located approximately 115 kilometers northwest of Fairbanks, Alaska in the Tolovana Mining District within the Tintina Gold Belt. The property is approximately 145 square kilometers and consists of fee land leased from the Alaska Mental Health Trust. The project area is centered on Money Knob. Advisors' Opinion:
  • [By Holly LaFon]

    He increased his holdings in gold companies in the fourth quarter accordingly. Gold stocks he found attractive in the fourth quarter are: Novagold Resources (NG), Randgold Resources (GOLD), Iamgold Corp. (IAG), Barrick Gold Corp. (ABX), Agnico Eagle (AEM) and International Tower Hill (THM).

  • [By Anthony Mirhaydari]

    For now, I continue to recommend investors maintain a cautious stance, focusing on the buying interest coming into safe-haven assets like U.S. Treasury bond and precious metals while booking profits in biotech stocks that have been red hot this month. The leveraged Direxion 3x Treasury Bond Bull (TMF) is up nearly 7% in my Edge Letter Sample Portfolio since it was added on Jan. 10. I just sold Tower Hill Mines (THM) and Rosetta Genomics (ROSG) for gains of 46% and 18% respectively.

  • [By Bryan Murphy]

    With no revenues, and therefore no profits, International Tower Hill Mines Ltd (NYSEMKT:THM) shouldn't qualify as "investment worthy" in any way, shape, or form. Indeed, the near-100% loss that THM shares have suffered since early 2011 might scare off even the gutsiest of traders. Yet, there's something undeniably bullish about this stock right now.

Top 10 Clean Energy Companies To Own For 2014: The Finish Line Inc.(FINL)

The Finish Line, Inc., together with its subsidiaries, operates as a mall-based specialty retailer in the United States. It operates Finish Line stores that offer performance and athletic casual footwear, apparel, and accessories for men, women, and kids. The company also sells merchandise through its Web site, finishline.com. As of September 22, 2011, it operated 646 stores in the United States. The company was founded in 1976 and is headquartered in Indianapolis, Indiana.

Advisors' Opinion:
  • [By Steve Symington]

    The plaintiff, a privately held footwear company named Gravity Defyer, is claiming Under Armour purposefully named select new styles of shoes to sound similar to its own trademarked G Defy line of products. As a result, the company says consumers are being "misled" into buying Under Armour's footwear when they may have instead been searching for Gravity Defyer's wares.

    But the retailers? Really?
    Now, Gravity Defyer just announced it has revised its lawsuit to name more than a dozen additional online retailers for their participation in the trademark infringement, including Finish Line (NASDAQ: FINL  ) , Foot Locker (NYSE: FL  ) and its Champs Sports subsidiary, Nordstrom,�Dick's Sporting Goods (NYSE: DKS  ) , Sport Chalet, Amazon.com� (NASDAQ: AMZN  ) and its Zappos subsidiary, Backcountry.com, Rogan's Shoes, Road Runner Sports Retail, MonkeySports, Holabird Sports, Eastbay, and Dodds Shoe Company.

  • [By Ben Levisohn]

    In our opinion, this was a fine quarter with no surprises; however, as we expected expenses are accelerating resulting in guidance that implies a meaningful reduction to Q3 and Q4 estimates. Also, gross margin headwinds are mounting as the favorability from raw materials has turned and supply chain disruptions in Mexico will persist for two Q��. Given NKE�� premium 25x multiple, we prefer to play its strength through its retail partners ([Foot Locker (FL) and Finish Line (FINL)]).

Top 10 Clean Energy Companies To Own For 2014: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors' Opinion:
  • [By Ben Levisohn]

    Consider: Shares of Gilead Sciences have risen just 3% so far in 2014, lagging Amgen’s (AMGN) 10% rise and Bioegen Idec’s (BIIB) 26% advance. The SPDR S&P Biotech ETF (XBI) has risen 24% so far this year.

  • [By Ben Levisohn]

    This year, Celgene has dropped 9.9%, even as other giant biotech companies like Biogen Idec (BIIB), Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN) has gained 7% or more. Even the SPDR S&P Biotech ETF (XBI) has managed to stay above water despite big March losses.

  • [By Ben Levisohn]

    Shares of Celgene gained 0.6% to $142.06 today, even as Amgen (AMGN) dropped 2% to 111.41, Biogen (BIIB) fell 3.1% to $285.81 and the SPDR S&P Biotech ETF (XBI) declined 3.9% to $124.37, extending its losing streak to three days. Gilead Sciences (GILD) dipped 0.2% to $73.90, ending a nine-day winning streak

No comments:

Post a Comment